Population-based reference for birth weight for gestational age in northern China

2014 ◽  
Vol 90 (4) ◽  
pp. 177-187 ◽  
Author(s):  
Zhe Liu ◽  
Jinliang Zhang ◽  
Baoxin Zhao ◽  
Xiaoping Xue ◽  
Lizhen Xu ◽  
...  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Na Zeng ◽  
Erica Erwin ◽  
Wendy Wen ◽  
Daniel J. Corsi ◽  
Shi Wu Wen ◽  
...  

Abstract Background Racial disparities in adverse perinatal outcomes have been studied in other countries, but little has been done for the Canadian population. In this study, we sought to examine the disparities in adverse perinatal outcomes between Asians and Caucasians in Ontario, Canada. Methods We conducted a population-based retrospective cohort study that included all Asian and Caucasian women who attended a prenatal screening and resulted in a singleton birth in an Ontario hospital (April 1st, 2015-March 31st, 2017). Generalized estimating equation models were used to estimate the independent adjusted relative risks and adjusted risk difference of adverse perinatal outcomes for Asians compared with Caucasians. Results Among 237,293 eligible women, 31% were Asian and 69% were Caucasian. Asians were at an increased risk of gestational diabetes mellitus, placental previa, early preterm birth (< 32 weeks), preterm birth, emergency cesarean section, 3rd and 4th degree perineal tears, low birth weight (< 2500 g, < 1500 g), small-for-gestational-age (<10th percentile, <3rd percentile), neonatal intensive care unit admission, and hyperbilirubinemia requiring treatment, but had lower risks of preeclampsia, macrosomia (birth weight > 4000 g), large-for-gestational-age neonates, 5-min Apgar score < 7, and arterial cord pH ≤7.1, as compared with Caucasians. No difference in risk of elective cesarean section was observed between Asians and Caucasians. Conclusion There are significant differences in several adverse perinatal outcomes between Asians and Caucasians. These differences should be taken into consideration for clinical practices due to the large Asian population in Canada.


2020 ◽  
Vol 226 ◽  
pp. 135-141.e4
Author(s):  
Kei Tamai ◽  
Takashi Yorifuji ◽  
Akihito Takeuchi ◽  
Yu Fukushima ◽  
Makoto Nakamura ◽  
...  

2011 ◽  
Vol 52 (4) ◽  
pp. 709-712 ◽  
Author(s):  
Svetlana V. Glinianaia ◽  
Mark S. Pearce ◽  
Judith Rankin ◽  
Tanja Pless-Mulloli ◽  
Louise Parker ◽  
...  

2015 ◽  
Vol 3 (1) ◽  
pp. 7
Author(s):  
Attila Vereczkey ◽  
Balázs Gerencsér ◽  
Andrew E Czeizel ◽  
István Szabó

<p><strong>Background:</strong> In general, previous epidemiological studies evaluated congenital heart defects (CHDs) together. The aim of the present study was to identify possible etiological factors of different CHD-entities, because the underlying causes are unclear in the vast majority of patients.</p><p><strong>Objectives:</strong> Different CHD-entities as homogeneously as possible with confirmed diagnoses were analyzed in the population-based large dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities.</p><p><strong>Methods</strong>: 3,750 live-born singleton CHD-patients were analyzed according to birth outcomes, i.e. gestational age at delivery and birth weight, the rate of preterm birth, low birthweight and small for gestational age.</p><p><strong>Results</strong>: The major findings of the study showed that cases with different CHD-entities had shorter gestational age at delivery and lower mean birth weight, and these variables associated with a higher rate of preterm birth and particularly with a much higher rate of low birthweight and small for gestational age. This study showed the importance of sex in the birth outcomes of some CHD-entities. The question is why several CHD-entities manifested more frequently in newborns with intrauterine growth restriction because fetal heart has a passive role before birth without pulmonary circulation.</p><p><strong>Conclusions:</strong> The birth outcomes of cases indicate the effect of CHDs for fetal development. In addition maternal confounders have to consider. Finally, CHDs and intrauterine growth restriction as two developmental errors may have a common route, thus fetal growth and birthweight associated gene polymorphisms may have a role in the origin of CHDs.</p>


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 79-79
Author(s):  
Rebecca James ◽  
Tom Johnston ◽  
Tracy Lightfoot ◽  
Dan Painter ◽  
Pat Ansell ◽  
...  

Abstract Abstract 79 Introduction: The Children with Down's Syndrome Study (CDSS; www.cdss.org.uk) is a unique observational study following a population-based cohort of children with Down's syndrome (DS) from birth onwards. Here we present the initial set of neonatal full blood count results - demonstrating that haematological values in DS neonates differ markedly from those of the general neonatal population; and providing, for the first time, DS specific reference ranges for haematological parameters for immediate clinical use. Methods: Recruitment to the population based CDSS opened in May 2006 and is ongoing. At entry, a blood sample taken in EDTA is sent to a designated laboratory with full CPA (UK) accreditation and processed using a Sysmex XE2100 or Advia 2120 according to a standard operating procedure. Clinical and demographic details, including date of birth, gestational age and birth weight are collected routinely. Of the 229 children recruited with appropriate samples, 197 are included in the analysis presented here: 32 were excluded because the sample was after 28 days of age; had a delay in processing; or had no result. Regression analyses considered effects of age at sampling, days until processing, sex, and source of sample. Gestational age and birth weight were examined in children sampled within 3 days of birth. Results: There were 109 boys and 88 girls. Median age at sampling was 3 days (IQR: 1–7). Median gestational age was 39 weeks (IQR: 37–39) and median birth weight was 3.0 kg (IQR: 2.4–3.4). The DS neonates had a similar RCC, but higher HB, HCT and MCV, when compared with standards for the general neonatal population: RCC 5.4 ± 0.82 x1012/l; HB 20.0 ± 3.3 g/dl with HCT 0.62 ± 0.1%, and MCV 115.5 ± 9.0 fl. By conventional standards, 43% of DS neonates would be considered to be polycythaemic (HCT>65%), and 76% macrocytic (MCV>110 fl). WCC was 13.9 ± 8.4 x109/l with differential analysis (on a subset of 100 children with suitable samples) showing neutrophils 6.4 ± 5.3 x109/l; lymphocytes 3.4 ± 2.0 x109/l; monocytes 0.97 ± 0.55 x109/l; eosinophils 0.22 ± 0.32 x109/l; and basophils 0.20 ± 0.19 x109/l. In 41% cases monocytes were >1.0 x109/l. The overall mean platelet count was 161 ± 89 x109/l. Thrombocytopenia was most common in the first week of life: 63% having platelets < 150 x109/l. Only 8% of children sampled in their fourth week of life had a platelet count < 150 x109/l. Mean MPV was 11.8 ± 1.0 fl which is greater than the 95th percentile MPV for a general neonatal population. HB, RCC, HCT, MCV, RDW-CV, nucleated red blood cells, WCC, neutrophils and lymphocytes all fell with each increasing day of age. These parameters did not vary with sex or source of sample. Platelet and monocyte number both increased slightly with increasing birth weight, while HB and RCC fell. HB, HCT, RCC and neutrophils increased with each week of increasing gestational age, while the platelet count fell. Conclusions: The haematological profile of DS neonates appears to be distinct from that of the general neonatal population reflecting altered trilineage haematopoiesis. The most striking features are the increased HB, HCT and MCV - with a preserved RCC; monocytosis; and thrombocytopenia with increased MPV. These features, particularly large haemoglobin-rich erythrocytes and thrombocytopenia, are associated with fetal haematopoiesis, suggesting that the switch to adult haematopoiesis may be delayed in DS. For example, the mean MCV here is comparable with that at 30 weeks gestation for the general population. Interestingly, the neutrophil count appears lower than the general population, although it follows a similar postnatal pattern: falling rapidly over the first few days before plateauing from day 10. Many neonatal units incorporate the neutrophil count in algorithms to indicate the likelihood of sepsis; these may need to be revised for DS neonates. Fetal thrombocytopenia has been described previously in DS. It is clear from this work that the platelet count increases with advancing postnatal age, so that in contrast to other causes of neonatal thrombocytopenia, a well DS neonate with thrombocytopenia does not require additional investigation. This work provides a much needed evidence-base for clinical practice: the predictive percentile charts indicating the expected range by age for the neonatal period and illustrating the natural history. Disclosures: No relevant conflicts of interest to declare.


BMJ Open ◽  
2018 ◽  
Vol 8 (11) ◽  
pp. e022565 ◽  
Author(s):  
Jufen Liu ◽  
Jing Xie ◽  
Zhiwen Li ◽  
Nicholas D E Greene ◽  
Aiguo Ren

ObjectivesSex differences in prevalence of neural tube defects (NTDs) have previously been recognised; however, the different susceptibility of men and women have not been examined in relation to the effects of folic acid (FA) supplementation. We hypothesised that FA may have a disproportionate effect that alters the sex-specific prevalence of NTDs.SettingData from two time points, before (2003–2004) and after (2011–2016) the start of the supplementation programme, were obtained from a population-based birth defect surveillance programme among five counties in northern China. All live births (28 or more complete gestational weeks), all stillbirths of at least 20 weeks’ gestational age and pregnancy terminations at any gestational age following the prenatal diagnosis of NTDs were included.ParticipantsA total of 25 249 and 83 996 births before and after the programme were included respectively.Primary and secondary outcome measuresThe prevalence of NTDs by sex and subtype, Male:female rate ratios and their 95% CI were calculated.ResultsOverall, NTDs were less prevalent among men than among women (rate ratio (RR) 0.92; 95% CI 0.90 to 0.94), so was anencephaly (RR 0.77; 95% CI 0.73 to 0.81) and encephalocele (RR 0.75; 95% CI 0.61 to 0.92), while spina bifida showed a male predominance (RR 1.10; 95% CI 1.05 to 1.15). The overall prevalence of NTDs decreased by 78/10 000 in men and 108.7/10 000 in women from 2003 to 2004 to 2011 to 2016. There was a significant sex difference in the magnitude of reduction, being greater in women than men, particularly for anencephaly.ConclusionsThe prevalence of NTDs decreased in both sexes after the implementation of a massive FA supplementation programme. While female predominance was observed in open NTDs and total NTDs, they also had a greater rate of decrease in NTDs after the supplementation programme.


2008 ◽  
Vol 192 (5) ◽  
pp. 338-343 ◽  
Author(s):  
Tim F. Oberlander ◽  
William Warburton ◽  
Shaila Misri ◽  
Jaafar Aghajanian ◽  
Clyde Hertzman

BackgroundLate-gestational serotonin reuptake inhibitor (SRI) exposure has been linked to adverse neonatal outcomes; however, the impact of timing and duration of exposure is unknown.AimsTo determine whether late-gestational exposure to an SRI is associated with increased risk of adverse neonatal outcome relative to early exposure.MethodPopulation-based maternal and neonatal health records were linked to prenatal maternal prescription records for an SRI medication (n=3500).ResultsAfter controlling for maternal illness and duration of exposure, using propensity score matching, neonatal outcomes did not differ between late and early exposure (PIQ>0.05). After controlling for maternal illness, longer prenatal exposure increased the risks of lower birth weight, respiratory distress and reduced gestational age (P<0.05).ConclusionsUsing population health data, length of gestational SRI exposure, rather than timing, increased the risk for neonatal respiratory distress, lower birth weight and reduced gestational age, even when controlling for maternal illness and medication dose. These findings highlight the importance of distinguishing the specific impact of medication exposure from exposure to maternal illness itself.


BMJ Open ◽  
2018 ◽  
Vol 8 (12) ◽  
pp. e022946 ◽  
Author(s):  
Natalie C Momen ◽  
Linn Håkonsen Arendt ◽  
Andreas Ernst ◽  
Jørn Olsen ◽  
Jiong Li ◽  
...  

ObjectivesThis study aims to estimate the association between pregnancy-associated maternal cancers, diagnosed both prenatally and postnatally, and birth outcomes.DesignPopulation-based register study.SettingNational registers of Denmark and Sweden.ParticipantsA total of 5 523 365 children born in Denmark (1977–2008) and Sweden (1973–2006).Primary and secondary outcome measures: gestational age, birth weight, size for gestational age, Apgar score, caesarean section and sex were the outcomes of interest. ORs and relative risk ratios (RRR) with 95% CIs were estimated using logistic regression and multinomial logistic regression, respectively.ResultsIn this study, 2% of children were born to mothers with a diagnosis of cancer. Children whose mothers received a prenatal cancer diagnosis had higher risk of being born preterm (RRR: 1.77, 95% CI 1.64 to 1.90); low birth weight (RRR 1.84, 95% CI 1.69 to 2.01); low Apgar score (OR 1.36, 95% CI 1.20 to 1.56); and by caesarean section (OR: 1.69, 95% CI 1.59 to 1.80). Associations moved towards the null for analyses using postnatal diagnoses, but preterm birth (RRR: 1.13, 95% CI 1.09 to 1.17) and low birth weight (RRR: 1.14, 95% CI 1.09 to 1.18) remained statistically significant, while risk of caesarean section became so (OR: 0.95, 95% CI 0.91 to 0.98). Additionally, statistical significance was reached for large for gestational age (RRR: 1.06, 95% CI 1.01 to 1.11), high birth weight (RRR: 1.04, 95% CI 1.01 to 1.06) and caesarean section (OR: 0.95, 95% CI 0.91 to 0.98).ConclusionsResults suggest an association between pregnancy-associated cancers and adverse birth outcomes in the offspring. While this is strongest for prenatally diagnosed cancers, some smaller associations exist for postnatally diagnosed cancers, indicating that cancer itself could affect fetal development, or that cancer and adverse birth outcomes share risk factors. Future studies on maternal cancer during pregnancy should consider including some postnatal years in their exposure window.


Sign in / Sign up

Export Citation Format

Share Document